Literature DB >> 24581918

Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.

Jie Gao1, Bao-Ling Adam1, Alvin V Terry2.   

Abstract

The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness. The purpose of the studies described here was to investigate the neuroprotective effects of the nicotine metabolite cotinine as well as a small series of cotinine and nicotine analogs (including stereoisomers) and to compare their effects to the four clinically prescribed AD therapies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyloid; Dementia; Disease modifying; Excitotoxicity; Glutamate; Multi-target-directed ligands; Multifunctional compounds; Neurodegeneration; Neuroprotection; Nicotinic

Mesh:

Substances:

Year:  2014        PMID: 24581918      PMCID: PMC4027973          DOI: 10.1016/j.bmcl.2014.02.008

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  32 in total

1.  Safety of cotinine in humans: physiologic, subjective, and cognitive effects.

Authors:  D K Hatsukami; M Grillo; P R Pentel; C Oncken; R Bliss
Journal:  Pharmacol Biochem Behav       Date:  1997-08       Impact factor: 3.533

2.  Nicotine regulates SH-SY5Y neuroblastoma cell proliferation through the release of brain-derived neurotrophic factor.

Authors:  Florence Serres; Stephen L Carney
Journal:  Brain Res       Date:  2006-06-21       Impact factor: 3.252

Review 3.  Multifunctional receptor-directed drugs for disorders of the central nervous system.

Authors:  Jerry J Buccafusco
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

4.  α7 Nicotinic receptor activation reduces β-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling.

Authors:  Wenfeng Yu; Naguib Mechawar; Slavica Krantic; Rémi Quirion
Journal:  J Neurochem       Date:  2011-10-03       Impact factor: 5.372

Review 5.  Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.

Authors:  Rafael León; Antonio G Garcia; José Marco-Contelles
Journal:  Med Res Rev       Date:  2011-07-26       Impact factor: 12.944

6.  Nature of nicotine binding to rat brain P2 fraction.

Authors:  J W Sloan; G D Todd; W R Martin
Journal:  Pharmacol Biochem Behav       Date:  1984-06       Impact factor: 3.533

Review 7.  Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

Authors:  Marina R Picciotto; Michele Zoli
Journal:  Front Biosci       Date:  2008-01-01

8.  Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain.

Authors:  D J Anderson; S P Arneric
Journal:  Eur J Pharmacol       Date:  1994-03-03       Impact factor: 4.432

9.  Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells.

Authors:  Karen Riveles; Luping Z Huang; Maryka Quik
Journal:  Neurotoxicology       Date:  2008-02-14       Impact factor: 4.294

Review 10.  Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.

Authors:  Jerry J Buccafusco; J Warren Beach; Alvin V Terry
Journal:  J Pharmacol Exp Ther       Date:  2008-11-20       Impact factor: 4.030

View more
  20 in total

1.  Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.

Authors:  Pei Li; Wayne D Beck; Patrick M Callahan; Alvin V Terry; Michael G Bartlett
Journal:  Pharmacol Rep       Date:  2014-12-16       Impact factor: 3.024

2.  Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome.

Authors:  Marta Pardo; Eleonore Beurel; Richard S Jope
Journal:  Eur J Neurosci       Date:  2016-11-12       Impact factor: 3.386

Review 3.  A decade of e-cigarettes: Limited research & unresolved safety concerns.

Authors:  Mohammad Abul Kaisar; Shikha Prasad; Tylor Liles; Luca Cucullo
Journal:  Toxicology       Date:  2016-07-28       Impact factor: 4.221

Review 4.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

5.  Diisopropylfluorophosphate Impairs the Transport of Membrane-Bound Organelles in Rat Cortical Axons.

Authors:  Jie Gao; Sean X Naughton; Heike Wulff; Vikrant Singh; Wayne D Beck; Jordi Magrane; Bobby Thomas; Navneet Ammal Kaidery; Caterina M Hernandez; Alvin V Terry
Journal:  J Pharmacol Exp Ther       Date:  2015-12-30       Impact factor: 4.030

6.  Chlorpyrifos and chlorpyrifos oxon impair the transport of membrane bound organelles in rat cortical axons.

Authors:  Jie Gao; Sean X Naughton; Wayne D Beck; Caterina M Hernandez; Guangyu Wu; Zhe Wei; Xiangkun Yang; Michael G Bartlett; Alvin V Terry
Journal:  Neurotoxicology       Date:  2017-06-12       Impact factor: 4.294

Review 7.  Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders.

Authors:  Alvin V Terry; Patrick M Callahan; Caterina M Hernandez
Journal:  Biochem Pharmacol       Date:  2015-07-29       Impact factor: 5.858

Review 8.  Cotinine: A Therapy for Memory Extinction in Post-traumatic Stress Disorder.

Authors:  Cristhian Mendoza; George E Barreto; Alexandre Iarkov; Vadim V Tarasov; Gjumrakch Aliev; Valentina Echeverria
Journal:  Mol Neurobiol       Date:  2018-01-15       Impact factor: 5.590

9.  Nicotinic receptor activation contrasts pathophysiological bursting and neurodegeneration evoked by glutamate uptake block on rat hypoglossal motoneurons.

Authors:  Silvia Corsini; Maria Tortora; Andrea Nistri
Journal:  J Physiol       Date:  2016-08-03       Impact factor: 5.182

Review 10.  New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine.

Authors:  J Alex Grizzell; Valentina Echeverria
Journal:  Neurochem Res       Date:  2014-06-27       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.